Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$1.49 +0.7%	$1.69	$1.20 ▼ $3.35	$4.80M	0.87	107,331 shs	12,669 shs
TTNP Titan Pharmaceuticals	$4.83 -1.4%	$4.44	$3.03 ▼ $8.44	$6.64M	1.29	51,600 shs	1,952 shs
VIVS VivoSim Labs	$2.11 +6.6%	$1.78	$1.41 ▼ $21.96	$5.49M	0.94	45,311 shs	46,081 shs
ZVSA ZyVersa Therapeutics	$0.14 -5.7%	$0.39	$0.11 ▼ $3.37	$1.10M	0.75	3.35 million shs	40,940 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	0.00%	+4.27%	-20.05%	-32.84%	-92.63%
TTNP Titan Pharmaceuticals	0.00%	-3.23%	-5.87%	+9.13%	-40.38%
VIVS VivoSim Labs	0.00%	+19.21%	-4.52%	+210,999,900.00%	+210,999,900.00%
ZVSA ZyVersa Therapeutics	0.00%	-10.23%	-42.25%	-74.33%	-96.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	0.3463 of 5 stars	0.0	3.0	0.0	0.0	2.8	0.0	0.0
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	0.6061 of 5 stars	0.0	4.0	0.0	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPHI China Pharma	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPHI China Pharma	$4.40M	1.11	N/A	N/A	$0.70 per share	2.13
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	$2.10 per share	N/A
VIVS VivoSim Labs	$140K	39.19	N/A	N/A	$3.67 per share	0.57
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	$3.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPHI China Pharma	-$3.08M	N/A	0.00	∞	N/A	-85.56%	-63.93%	-31.42%	N/A
TTNP Titan Pharmaceuticals	-$4.71M	-$2.95	N/A	∞	N/A	N/A	-108.60%	-95.64%	N/A
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,396.48%	-32.95%	-21.31%	N/A
ZVSA ZyVersa Therapeutics	-$9.41M	N/A	0.00	N/A	N/A	N/A	-109.54%	-43.95%	N/A

Latest ZVSA, VIVS, TTNP, and CPHI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	TTNP Titan Pharmaceuticals	N/A	-$0.65	N/A	-$0.65	N/A	N/A
8/12/2025	Q1 2026	VIVS VivoSim Labs	N/A	-$1.14	N/A	-$1.14	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A
ZVSA ZyVersa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPHI China Pharma	0.22	0.79	0.26
TTNP Titan Pharmaceuticals	N/A	11.60	7.73
VIVS VivoSim Labs	N/A	4.52	4.52
ZVSA ZyVersa Therapeutics	N/A	0.18	0.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPHI China Pharma	N/A
TTNP Titan Pharmaceuticals	31.49%
VIVS VivoSim Labs	8.23%
ZVSA ZyVersa Therapeutics	3.91%

Insider Ownership

Company	Insider Ownership
CPHI China Pharma	17.32%
TTNP Titan Pharmaceuticals	0.72%
VIVS VivoSim Labs	3.72%
ZVSA ZyVersa Therapeutics	0.21%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPHI China Pharma	250	3.26 million	15.92 million	Not Optionable
TTNP Titan Pharmaceuticals	10	1.33 million	1.32 million	Optionable
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A
ZVSA ZyVersa Therapeutics	2	7.94 million	4.86 million	Not Optionable

ZVSA, VIVS, TTNP, and CPHI Headlines

Recent News About These Companies

ZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq Delisting

August 20, 2025 | msn.com

ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...

August 14, 2025 | bakersfield.comB

ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD

August 14, 2025 | msn.com

ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

August 14, 2025 | globenewswire.com

ZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product Development

August 13, 2025 | quiverquant.comQ

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

August 13, 2025 | globenewswire.com

ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

July 21, 2025 | globenewswire.com

ZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading Thursday

July 16, 2025 | marketwatch.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | Morningstar

July 9, 2025 | morningstar.comM

ZyVersa’s VAR 200 approved for emergency use in rare kidney disease

July 9, 2025 | uk.investing.com

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - Nasdaq

July 9, 2025 | nasdaq.com

Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?

July 8, 2025 | benzinga.com

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | finanznachrichten.de

ZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis

July 8, 2025 | quiverquant.comQ

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediatorâ„¢Â VAR 200 in a Patient with ApoCII Amyloidosis

July 8, 2025 | globenewswire.com

ZyVersa Therapeutics Enters Share Purchase Agreement with Williamsburg Venture Holdings to Advance Clinical Development of VAR 200 - Nasdaq

June 27, 2025 | nasdaq.com

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol ...

June 26, 2025 | morningstar.comM

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients ...

June 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA, VIVS, TTNP, and CPHI Company Descriptions

China Pharma NYSE:CPHI

$1.50 +0.02 (+1.01%)

As of 08/22/2025 04:00 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Titan Pharmaceuticals NASDAQ:TTNP

$4.83 -0.07 (-1.45%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$4.83 +0.00 (+0.02%)

As of 08/22/2025 06:31 PM Eastern

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

VivoSim Labs NASDAQ:VIVS

$2.11 +0.13 (+6.57%)

As of 08/22/2025 03:59 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

ZyVersa Therapeutics NASDAQ:ZVSA

$0.14 -0.01 (-5.71%)

As of 08/22/2025 03:17 PM Eastern

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time